Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of JNJ-64140284 in Healthy Men
NCT04033458Phase 1Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2019
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of JNJ-64140284 in epilepsy (10 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Peak Plasma Concentration, Area Under The Plasma Concentration-time Curve From 0 to t Hours and 2 more. Started Jul 2019; status: terminated.
02
Drugs
JNJ-64140284
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT04033458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04033458.